"Vaccine side reaction" of Nuvaxovid vaccine, "1/4" compared to other vaccines = Korea

It was found that there were significantly fewer reports of adverse reactions to the Novabax COVID-19 virus infection vaccine, which began in February in South Korea.

According to the material of "Novaxovid Vaccination Monitoring Status after Vaccination" released on18th by the Korea COVID-19 Vaccination Promotion Team in "Weekly Health and Diseases" of the Disease Control Agency, Novaxovid vaccination from February 14th to May 7th, there were a total of 666 cases of post-Novaxovid vaccination adverse reactions reported to the COVID-19 vaccination management system. The number of Novabax vaccinations during the same period was 430,339, and the number of reported adverse reactions per 100,000 was "154.8".

This is about 16-50% of other vaccines such as Janssen (586.7 cases per 100,000 people), AstraZeneca (539.1 cases), Moderna (464.7 cases) and Pfizer (309.7 cases).

Novabax vaccine is a messenger ribonucleic acid (RNA) vaccine, Pyzer, Moderna, and viral vector vaccine, which was developed by the gene recombination (synthetic antigen) method that has been used for a long time in existing vaccines such as hepatitis B and influenza. Compared to AstraZeneca Janssen, there is less concern and resistance to side reactions.

However, the COVID-19 Vaccination Response Promotion Team said, "In the case of the Novabax vaccine, the observation period after vaccination is relatively short compared to other vaccines, so care must be taken in interpreting the results."